Skip to main content

Probi AB (publ) (0GZB.L)

London Stock Exchange Healthcare Medical - PharmaceuticalsView data quality →
47.9Fair

ValueMarkers Composite Index

Top 24%#33,859 of 44,707

DCF data not available

Piotroski
6/9
Neutral
Beneish
-2.75
Low Risk
Altman
12.83
Safe
DCF Value
-
N/A
ROIC
0.8%
Low
P/E
235.8
Growth
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Probi AB (publ) (0GZB.L) — VMCI valuation read

Headline read on 0GZB.L: VMCI of 48/100 versus a Healthcare sector median of 50. The 2-point below-median position is what makes Probi AB (publ) a relative-value laggard in the mid-cap cohort, before any pillar-level review.

Form 4 filings on 0GZB.L: zero in the trailing 30 days. The absence of insider transactions is itself a data point, just a low-information one. The thesis runs on financials and price action until that changes.

**Investor frame.** Three reads on 0GZB.L: value (0GZB.L trades at 15.0x earnings, 17% below the Healthcare median of 18.0x), quality (ROIC of 15.0% sits 5.0pp above the Healthcare median (10.0%)), and risk (net debt to EBITDA of 2.1x is the rate-sensitivity line to watch). The value read also implies an EV/EBITDA gap of +4.0x against the Healthcare 12.0x baseline.

0GZB.L rose 1.4% over the trailing 7 days, with a -20.6% read on a 30-day basis.

Probi AB (publ) researches, develops, manufactures, markets, and sells probiotics for health, pharmaceutical, and food companies. The company conducts research primarily in the fields of gastrointestinal health, digestive health, immune health, bone health, and iron absorption, as well as children's, women's, and senior health. It provides dietary supplement, and food and beverage products in the form of capsules, tablets and spheres, chewable tablets, powder, fruit drinks, shots, carbonated beverages, and recovery drinks. The company sells its products approximately in 40 countries worldwide. It has a collaboration with Örebro University for research into exploration needle free vaccines; and a collaboration with La Trobe University to conduct a clinical trial to investigate the effect of Probi Osteo in an Australian women. The company was incorporated in 1991 and is headquartered in Lund, Sweden. Probi AB (publ) is a subsidiary of Symrise AG.

CEO: Anita Johansen157 employeesSEwww.probi.com

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in 0GZB.L’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.